DE3889783T2 - Verwendung von Antikörper-Antigen-Wechselwirkung zum Schutz oder Modulation der biologischen Aktivität. - Google Patents

Verwendung von Antikörper-Antigen-Wechselwirkung zum Schutz oder Modulation der biologischen Aktivität.

Info

Publication number
DE3889783T2
DE3889783T2 DE3889783T DE3889783T DE3889783T2 DE 3889783 T2 DE3889783 T2 DE 3889783T2 DE 3889783 T DE3889783 T DE 3889783T DE 3889783 T DE3889783 T DE 3889783T DE 3889783 T2 DE3889783 T2 DE 3889783T2
Authority
DE
Germany
Prior art keywords
antibody
biological activity
molecule
complex
inactivation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3889783T
Other languages
English (en)
Other versions
DE3889783D1 (de
Inventor
Ezekiel Y Shami
Aser Rothstein
Mohabir Ramjeesingh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybrisens Ltd
Original Assignee
Hybrisens Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybrisens Ltd filed Critical Hybrisens Ltd
Publication of DE3889783D1 publication Critical patent/DE3889783D1/de
Application granted granted Critical
Publication of DE3889783T2 publication Critical patent/DE3889783T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82—Asparaginase (3.5.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE3889783T 1987-07-07 1988-06-30 Verwendung von Antikörper-Antigen-Wechselwirkung zum Schutz oder Modulation der biologischen Aktivität. Expired - Fee Related DE3889783T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7186187A 1987-07-07 1987-07-07
US18253088A 1988-04-18 1988-04-18
US20574888A 1988-06-21 1988-06-21

Publications (2)

Publication Number Publication Date
DE3889783D1 DE3889783D1 (de) 1994-07-07
DE3889783T2 true DE3889783T2 (de) 1994-09-08

Family

ID=27371979

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3889783T Expired - Fee Related DE3889783T2 (de) 1987-07-07 1988-06-30 Verwendung von Antikörper-Antigen-Wechselwirkung zum Schutz oder Modulation der biologischen Aktivität.

Country Status (7)

Country Link
EP (1) EP0298654B1 (de)
JP (1) JPH01138461A (de)
AT (1) ATE106250T1 (de)
AU (1) AU1865288A (de)
DE (1) DE3889783T2 (de)
DK (1) DK375188A (de)
ES (1) ES2056108T3 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686579A (en) * 1988-06-21 1997-11-11 Hybrisens, Ltd. Use of antibody/antigen interactions to protect biologically active proteins and peptides
JPH03133378A (ja) * 1989-07-19 1991-06-06 Modrovich Ivan E 被験体を安定化させて液体中でのその生物学的活性を保存する方法
DK0487301T3 (da) * 1990-11-20 2000-09-18 Dade Behring Marburg Gmbh Fremgangsmåde til stabilisering af enzymkonjugater
AU6849796A (en) * 1996-08-16 1998-03-06 Procter & Gamble Company, The Detergent compositions comprising antibody controlled enzymatic activity
WO1998007821A1 (en) * 1996-08-16 1998-02-26 The Procter & Gamble Company Detergent compositions comprising antibody controlled cellulolytic activity
WO1998007817A1 (en) * 1996-08-16 1998-02-26 The Procter & Gamble Company Detergent compositions comprising antibody controlled lipolytic activity
WO1998007816A1 (en) * 1996-08-16 1998-02-26 The Procter & Gamble Company Detergent compositions comprising oxido-reductase antibody
WO1998007818A1 (en) * 1996-08-16 1998-02-26 The Procter & Gamble Company Detergent compositions comprising antibody controlled amylolytic activity
WO1998007819A1 (en) * 1996-08-16 1998-02-26 The Procter & Gamble Company Detergent compositions comprising antibody controlled proteolytic activity
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20070202099A1 (en) * 2004-03-30 2007-08-30 Hiroshi Inooka Antibody Drug
CN101724071A (zh) * 2004-10-08 2010-06-09 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
JP2009525319A (ja) 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
EP0231649B1 (de) * 1985-12-28 1990-11-22 Nippon Hypox Laboratories Incorporated Albumin-Komplex
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides

Also Published As

Publication number Publication date
DE3889783D1 (de) 1994-07-07
AU1865288A (en) 1989-01-12
EP0298654A2 (de) 1989-01-11
DK375188A (da) 1989-01-08
ES2056108T3 (es) 1994-10-01
ATE106250T1 (de) 1994-06-15
EP0298654A3 (en) 1990-02-07
JPH01138461A (ja) 1989-05-31
DK375188D0 (da) 1988-07-06
EP0298654B1 (de) 1994-06-01

Similar Documents

Publication Publication Date Title
DE3889783D1 (de) Verwendung von Antikörper-Antigen-Wechselwirkung zum Schutz oder Modulation der biologischen Aktivität.
DE68903558T2 (de) Verfahren zur inaktivierung von viren.
ATE68015T1 (de) Herstellung von mikrobieller zellulose.
ATE42206T1 (de) Verfahren und zusammensetzung zur gleichzeitigen reinigung und desinfektion von kontaktlinsen.
ATE5898T1 (de) Verfahren zur enzymatischen glucoseoxidation.
ATE184289T1 (de) Ribosomen-inaktivierende proteine, inaktive vorläuferformen derselben, verfahren zur herstellung und eine methode zur nutzung
ATE525390T1 (de) Verwendung von resistin spezifischen antikörpern in der behandlung von diabetes
DE3884895D1 (de) Verwendung von Bezafibrat zur Behandlung von Diabetes.
DE69022909D1 (de) Enzymatische Oxidation von Ceph C zu Glutaryl-7-Aminocephalosporansäure.
ATE36557T1 (de) Verfahren zur bestimmung der wirksamkeit von substraten oder enzymen.
YU88092A (sh) Enzimatski postupak za enantioselektivno pripremanje optički aktivnih cijanhidrina
ES478533A1 (es) Un procedimiento para eliminar melamina de liquidos que con-tienen melamina.
ATE54065T1 (de) Katalysatorherstellung.
DE58905691D1 (de) Verfahren zur Herstellung von L-alpha-Aminosäuren.
DK0457035T3 (da) Fremgangsmåde til inaktivering af den biologiske aktivitet af DNA
DK710588D0 (da) Enzym samt fremgangsmaade til enzymatisk hydrolyse af alfa-aminoadipinyl-monoaminoforbindelser
DE3889845D1 (de) Verfahren zur Massanalyse von Wasserstoff-Peroxyd und Reagens dafür.
SE8600987D0 (sv) Forfarande for framstellning av ett protein- koncentrat ur helblod
ATE4326T1 (de) Verfahren zur gewinnung von cholesterinesterase.
ATE273712T1 (de) Methode zur inaktivierung von proteinen der ras- unterfamilie und verbindungen dafuer
DE3775866D1 (de) Verfahren zur durchfuehrung enzymatischer oxidationen.
ATE56684T1 (de) Verfahren zur herstellung von ndichlorphosphoryltrichlorphosphazen aus phosphorpentachlorid und ammoniumchlorid.
DK421386D0 (da) Fremgangsmaade til submers dyrkning af pseudomonas aeruginosa bakteriestammer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee